Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M.G. Costa
Psy23 - Agalsidase Alfa and Agalsidase Beta for Treatment of Fabry Disease
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Comparison of the Effects of Agalsidase Alfa and Agalsidase Beta on Cultured Human Fabry Fibroblasts and Fabry Mice
Journal of Human Genetics
Genetics
Biventricular Cardiomyopathy Improvement by Shifting Therapy From Agalsidase Alfa to Agalsidase Beta in Anderson-Fabry Disease (RCD Code: III-3B.2)
Journal of Rare Cardiovascular Diseases
Cardiovascular Medicine
Cardiology
The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy
Clinical Journal of the American Society of Nephrology
Epidemiology
Nephrology
Critical Care
Transplantation
Intensive Care Medicine
Clinical Course of Patients With Fabry Disease Who Were Switched From Agalsidase-Β to Agalsidase-Α
Genetics in Medicine
Medicine
Genetics
Letter Concerning “Enzyme Replacement Therapy in a Patient With Fabry Disease and the Development of IgE Antibodies Against Agalsidase Beta but Not Agalsidase Alpha”, by Tanaka Et Al.
Journal of Inherited Metabolic Disease
Genetics
Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease
Clinical Journal of the American Society of Nephrology
Epidemiology
Nephrology
Critical Care
Transplantation
Intensive Care Medicine
Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase Beta Therapy in Patients With Fabry Disease
Journal of the American Society of Nephrology : JASN
Medicine
Nephrology
Screening, Diagnosis and Treatment of Fabry Disease
Clinical pharmacology and therapy
Time Delays in the Diagnosis and Treatment of Fabry Disease
International Journal of Clinical Practice
Medicine
